Table 3.

Key supply-side policies for biosimilars.

Policy	Belgium	France	Germany	Greece	Hungary	Italy	Polanda	Spain	Sweden	UK
IRP	×	✓	✓	×	✓	×	✓	✓	×	×
ERP	×	×	×	✓	×	✓	✓	×	×	×
HTA	✓	✓	×	×	×	✓	✓b	×	✓	✓
Price linkage	✓	✓	✓	×	✓c	✓c	✓c	✓	✓	✓
Price re-evaluation	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Tendering	✓	✓	✓	×	✓	✓	✓	✓	✓	✓

IRP: internal reference pricing; ERP: external reference pricing; HTA: health technology assessment; ×: absence of policy; ✓: presence of policy.

^a Polish regulations do not differentiate between small molecule generics and biosimilars.

^b Only when there is no equivalent medicine on the market.

^c Mandatory price reduction (defined price cut).